Description

Vectura Group Plc engages in the provision of pharmaceutical development. The company is headquartered in Chippenham, Wiltshire and currently employs 453 full-time employees. The firm's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Address